Integrity, Transparency and Speed: AAM Member Meitheal
The word meitheal (pronounced mee-hall) captures the Irish tradition of working together for the greater good. Launched in 2017, the rapidly growing, Chicago-based pharmaceutical manufacturer of the same name has over 37 generic injectable molecules on market, with many more expected this year.
Meitheal develops, manufactures, procures, and sells generic injectable pharmaceuticals. While the company’s focus has been generics, Meitheal has made new key hires to the organization focusing on biopharmaceuticals.
Our purpose, says founding CEO Tom Shea,
is to simplify access to life-changing medicines, for good. We strive to provide reliable, sustainable solutions.
Becoming a member of AAM in 2022 is helping the company to fulfill this objective, Shea adds.
We can lend our voice to support our industry and work with legislatures to ensure their policy initiatives appreciate a sustainable market is needed to ensure patient access to safe, effective and affordable generic, complex generic and biosimilar medicines.
During the COVID pandemic, Meitheal became the market leader in supplying Enoxaparin injection, explaining that it was
proud to offer and provide a much-needed product during [the] pandemic. Meitheal’s commitment to access also includes actively working with nonprofits to donate key lifesaving medicines for patients in Ukraine.
By Jewel Smith, Vice President, Membership and Operations
Published on October 14, 2022